Previous 10 | Next 10 |
NEW HAVEN, Conn., May 20, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that its 2020 Annual Meeting of Stockholders, to be held on Wednesday, June 3, 2020 at...
Gainers: Applied DNA Sciences (NASDAQ: APDN ) +51% . More news on: Applied DNA Sciences, Inc., Akers Biosciences, Inc., Glory Star New Media Group Holdings Limited, Stocks on the move, , Read more ...
Comstock Resources (NYSE: CRK ) -32% after pricing 40M-share offering at $5/share. More news on: Comstock Resources, Inc., MacroGenics, Inc., Arvinas, Inc., Stocks on the move, , Read more ...
Arvinas (NASDAQ: ARVN ) is down 16% premarket on light volume after the release of an abstract on a Phase 1 clinical trial evaluating protein degrader ARV-110 in patients with metastatic treatment-resistant prostate cancer, the first in-human data on a drug with this mechanis...
Arvinas (NASDAQ: ARVN ) down 28.9% post market, after the company announces updated safety and initial efficacy data from the dose escalation portion of its Phase 1/2 clinical trial of ARV-110. More news on: Arvinas, Inc., Healthcare stocks news, Read more ...
- Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality - - Data to be presented during the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting - NEW HAVEN, Conn., May 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc...
Many investors tend to stay away from stocks that are appreciating strongly over time, mostly because of fears of buying too late when the stock is already overvalued. Having some patience when looking for entry prices and being conscious about valuation is very important. However, blindly avo...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Arvinas (NASDAQ: ARVN ): Q1 GAAP EPS of -$0.56 beats by $0.03 . More news on: Arvinas, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
NEW HAVEN, Conn., April 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today provided an update regarding the impact of the COVID-19 pandemic on its overall business conti...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ann...